In December 2017, Navigen created a wholly owned subsidiary, A6 Pharmaceuticals, to focus on advancing the ARF6 inhibitor programs.
ARF6 plays a critical role in pathologic protein trafficking in conditions as seemingly diverse as acute lung injury and melanoma. A6 Pharmaceuticals has identified proprietary small molecule inhibitors of ARF6. Using these compounds, it has demonstrated efficacy in in vivo models of disease including uveal melanoma, malignant sarcoma, acute lung injury/acute respiratory distress syndrome, multi-drug resistant gram negative bacterial pneumonia, and diabetic retinopathy. For more information, please visit www.A6pharma.com.